Search Result

Results for "

IPF,

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (5) Btk (1) Calcium Channel (1) EGFR (1) Endothelin Receptor (4) Ephrin Receptor (1) HDAC (1) Integrin (2) Isotope-Labeled Compounds (3) JAK (2) LPL Receptor (2) MMP (2) mTOR (2) Phosphodiesterase (PDE) (2) PI3K (3) STAT (1) TGF-β Receptor (2)
By Research Areas:	Cancer (10) Cardiovascular Disease (4) Endocrinology (3) Inflammation/Immunology (13) Metabolic Disease (2)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99288

FG-3019 Pamrevlumab; Anti-Human CTGF Recombinant Antibody	Apoptosis	Cancer
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .

HY-14184

Macitentan Maximum Cited Publications 10 Publications Verification ACT-064992	Endothelin Receptor Apoptosis	Cardiovascular Disease Endocrinology Cancer
Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .

HY-14184A

Macitentan (n-butyl analogue)	Endothelin Receptor	Cardiovascular Disease Endocrinology
Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

HY-14184S

Macitentan-d4 ACT-064992-d₄	Isotope-Labeled Compounds Endothelin Receptor Apoptosis	Cardiovascular Disease
Macitentan-d₄ is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].

HY-120981S

*(±)5-iPF2α-VI-d11*	Isotope-Labeled Compounds	Others
(±)5-iPF2α-VI-d₁₁ is the deuterium labeled (±)5-iPF2α-VI[1].

HY-137119

*(±)5-iPF2α-VI* 5-iso Prostaglandin F2α-VI	Others	Others
(±)5-iPF2α-VI (5-iso Prostaglandin F2α-VI) is the racemate of 5-iPF2α-VI. 5-iPF2α-VI is a regioisomeric isoprostane formed from arachidonic acid (AA) and is a biomarker of oxidative stress .

HY-137119A

*8,12-iso-iPF2α-VI*	Others	Others
8,12-iso-iPF2α-VI is a F2-isoprostanes. 8,12-iso-iPF2α-VI is a sensitive and specific marker of in vivo lipid peroxidation. 8,12-iso-iPF2α-VI can be used as a biomarker of oxidative damage in alzheimer's disease .

HY-137119AS

*8,12-iso-iPF2α-VI-d11*	Isotope-Labeled Compounds	Others
8,12-iso-iPF2α-VI-d₁₁ is the deuterium labeled 8,12-iso-iPF2α-VI[1].

HY-151955

TGFβ1-IN-3	TGF-β Receptor	Inflammation/Immunology
TGFβ1-IN-3 is a diarylacylhydrazones derivative that effectively suppresses the activation and proliferation of fibroblasts. TGFβ1-IN-3 can be used for idiopathic pulmonary fibrosis (IPF) research .

HY-151954

TGFβ1-IN-2	TGF-β Receptor	Inflammation/Immunology
TGFβ1-IN-2 is a diarylacylhydrazones derivative that effectively suppresses the activation and proliferation of fibroblasts. TGFβ1-IN-2 can be used for idiopathic pulmonary fibrosis (IPF) research .

HY-147741

DPPY	JAK Btk EGFR	Inflammation/Immunology Cancer
DPPY (compound 6) is a potent PTK inhibitor with IC₅₀ values of <10, <10, <10 nM for EGFR, BTK, JAK3, respectively. DPPY shows anti-proliferative activity against B-cell lymphoma cells. DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF) .

HY-P99351

Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)	MMP	Cancer
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .

HY-145358

FAP-PI3KI1	PI3K	Cancer
FAP-PI3KI1 is a fibroblast-activated protein (FAP)-targeted PI3K inhibitor that selectively targets FAP-expressing human idiopathic pulmonary fibrosis (IPF) cells and effectively inhibits collagen synthesis and reduces collagen deposition .

HY-14184R

Macitentan (Standard)	Endothelin Receptor Apoptosis	Cardiovascular Disease Endocrinology Cancer
Macitentan (Standard) is the analytical standard of Macitentan. This product is intended for research and analytical applications. Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .

HY-147936

TP0556351	MMP	Inflammation/Immunology
TP0556351 is a potent and selective matrix metalloproteinase-2 (MMP2) inhibitor with an IC₅₀ value of 0.2 nM. TP0556351 reduces the amount of collagen in the lungs of a Bleomycin-induced pulmonary fibrosis mouse model. TP0556351 can be used for researching idiopathic pulmonary fibrosis (IPF) .

HY-P99655

Ifabotuzumab KB004	Ephrin Receptor Apoptosis	Cancer
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K_D=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10 ⁺ cells and improves pulmonary fibrosis .

HY-147742

Thi-DPPY	JAK	Inflammation/Immunology
Thi-DPPY (compound 8e) is a potent and orally active JAK3 inhibitor with IC₅₀ values of 62.4, 1.38 nM for BTK, JAK, respectively. Thi-DPPY shows anti-proliferative activity against HBE cells. Thi-DPPY shows anti-inflammatory activity in vivo. Thi-DPPY has the potential for the research of idiopathic pulmonary fibrosis (IPF) .

HY-151976

STAT3-IN-15 1 Publications Verification	STAT	Inflammation/Immunology
STAT3-IN-15 is a potent and orally active STAT3 inhibitor against idiopathic pulmonary fibrosis (IPF). STAT3-IN-15 inhibits STAT3 phosphorylation. STAT3-IN-15 also inhibits the migration and deformation of epithelial cells induced by TGF-β1 and inhibit epithelial-mesenchymal transition (EMT) .

HY-153120A

PI3K/mTOR Inhibitor-13 sodium	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-153120

PI3K/mTOR Inhibitor-13	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-137561A

Bexotegrast hydrochloride PLN-74809 hydrochloride	Integrin	Inflammation/Immunology
Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts .

HY-100619A

BMS-986020 sodium 5+ Cited Publications AM152 sodium	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-144743

ATX inhibitor 12	Phosphodiesterase (PDE)	Others
ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC₅₀ of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .

HY-100619

BMS-986020 5+ Cited Publications AM152	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-137464A

OATD-01 1 Publications Verification	Others	Inflammation/Immunology
OATD-01 is a highly potent, first-in-class, orally active and selective chitinase inhibitor with low nanomolar activity toward CHIT1 (hCHIT1,IC₅₀=23 nM). OATD-01 shows excellect PK profile in multiple species and is selectivity against a panel of other off-targets. OATD-01 exhibits significant antifibrotic efficacy in vivo and can be used for pulmonary fibrosis (IPF) research .

HY-164360

αVβ8-IN-1	Integrin	Inflammation/Immunology Cancer
αVβ8-IN-1 is a αVβ8 integrin inhibitor. αVβ8-IN-1 has been shown to inhibit the growth of tumors such as EMT6, CT26, KPC, and TKCC-10. αVβ8-IN-1 can be used in research related to idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and tumors .

HY-162630

HDAC6-IN-44	HDAC	Inflammation/Immunology
HDAC6-IN-44 (compound H10) is a selective HDAC6 inhibitor with an IC₅₀ value of 8.97 nM. HDAC6-IN-44 can inhibit the idiopathic pulmonary fibrosis (IPF) phenotype and exhibits antifibrotic activity. Additionally, HDAC6-IN-44 reduces fibrogenesis in a bleomycin-induced pulmonary fibrosis mouse model and demonstrates good metabolic stability. HDAC6-IN-44 holds promise for research in the field of idiopathic pulmonary fibrosis .

HY-147946

PDE1-IN-4	Phosphodiesterase (PDE) Calcium Channel	Inflammation/Immunology
PDE1-IN-4 (compound 2g) is a potent and selective PDE1 (phosphodiesterase-1) inhibitor, with IC₅₀ values of 10, 145, and 354 nM for PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research .

Cat. No.	Product Name

HY-L125

Anti-Pulmonary Fibrosis Compound Library	1,764 compounds
Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 1,764 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.

Anti-Pulmonary Fibrosis Compound Library

1,764 compounds

Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 1,764 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P99288

FG-3019 Pamrevlumab; Anti-Human CTGF Recombinant Antibody	Apoptosis	Cancer
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .

HY-P99351

Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)	MMP	Cancer
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .

HY-P99655

Ifabotuzumab KB004	Ephrin Receptor Apoptosis	Cancer
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K_D=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10 ⁺ cells and improves pulmonary fibrosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99288

FG-3019 Pamrevlumab; Anti-Human CTGF Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	Apoptosis
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .

HY-P99351

Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)	Classification of Application Fields Disease Research Fields Cancer	MMP
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .

HY-P99655

Ifabotuzumab KB004	Classification of Application Fields Disease Research Fields Cancer	Ephrin Receptor Apoptosis
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (K_D=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10 ⁺ cells and improves pulmonary fibrosis .

Cat. No.	Product Name	Chemical Structure

HY-14184S

Macitentan-d4
Macitentan-d₄ is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].

HY-120981S

*(±)5-iPF2α-VI-d11*
(±)5-iPF2α-VI-d₁₁ is the deuterium labeled (±)5-iPF2α-VI[1].

HY-137119AS

*8,12-iso-iPF2α-VI-d11*
8,12-iso-iPF2α-VI-d₁₁ is the deuterium labeled 8,12-iso-iPF2α-VI[1].

HY-169071S

ATX-1905
ATX-1905 is a positron emission tomography (PET) tracer that demonstrates good autotaxin (ATX) binding specificity and achieves semiquantification of lung ATX expression levels, which are elevated in fibrotic lungs. ATX-1905 exhibits elevated uptake in Bleomycin (HY-108345)-induced pulmonary fibrosis (BPF) lungs. ATX-1905 is promising for research of idiopathic pulmonary fibrosis (IPF) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

IPF,

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products